pegaptanib ophthalmic (Macugen)

From Aaushi
Jump to navigation Jump to search
[1][2]

Introduction

Tradename: Macugen (FDA-approved in 2004)

Indications

Dosage

intravitreous injection every 6 weeks[2]

Adverse effects

Mechanism of action

Notes

Manufacturer: Eyetech/Pfizer

More general terms

Additional terms

References

  1. ↑ Prescriber's Letter 12(2): 2005 New Drugs Approved by the FDA in 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210216&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. ↑ 2.0 2.1 2.2 FDA Medwatch http://www.fda.gov/medwatch/safety/2006/safety06.htm#Macugen
Retrieved from "https://aaushi.info/w/index.php?title=A392521&oldid=937010"